Total Payments
$489,190
2024 Payments
$16,419
Companies
42
Transactions
1,430
Medicare Patients
58,267
Medicare Billing
$10.1M
Payment Breakdown by Category
Other$397,039 (81.2%)
Travel$48,494 (9.9%)
Food & Beverage$27,726 (5.7%)
Consulting$13,950 (2.9%)
Education$1,032 (0.2%)
Research$948.92 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $363,839 | 175 | 74.4% |
| Travel and Lodging | $48,494 | 151 | 9.9% |
| Honoraria | $33,200 | 7 | 6.8% |
| Food and Beverage | $27,726 | 1,065 | 5.7% |
| Consulting Fee | $13,950 | 7 | 2.9% |
| Education | $1,032 | 22 | 0.2% |
| Unspecified | $948.92 | 3 | 0.2% |
Payments by Type
General
$488,241
1,427 transactions
Research
$948.92
1 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $247,555 | 472 | $0 (2024) |
| Lilly USA, LLC | $151,484 | 269 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $76,799 | 84 | $0 (2024) |
| Janssen Biotech, Inc. | $1,795 | 75 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,497 | 89 | $0 (2024) |
| Eli Lilly and Company | $948.92 | 1 | $0 (2018) |
| Amgen Inc. | $908.64 | 37 | $0 (2024) |
| UCB, Inc. | $889.43 | 39 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $811.69 | 32 | $0 (2024) |
| LEO Pharma Inc. | $783.21 | 40 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,419 | 140 | ABBVIE INC. ($9,913) |
| 2023 | $40,874 | 145 | Sun Pharmaceutical Industries Inc. ($21,060) |
| 2022 | $34,901 | 150 | Sun Pharmaceutical Industries Inc. ($15,130) |
| 2021 | $58,969 | 138 | SUN PHARMACEUTICAL INDUSTRIES INC. ($35,911) |
| 2020 | $23,135 | 118 | AbbVie Inc. ($14,892) |
| 2019 | $102,809 | 223 | AbbVie, Inc. ($79,939) |
| 2018 | $147,471 | 315 | Lilly USA, LLC ($85,427) |
| 2017 | $64,613 | 201 | AbbVie, Inc. ($45,577) |
All Payment Transactions
1,430 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $475.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $11.67 | General |
| Category: Immunology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.10 | General |
| Category: Immunology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $2.40 | General |
| Category: Immunology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $0.45 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $11.11 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $14.79 | General |
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: DERMATOLOGY | ||||||
| 11/18/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | ConvaTec Inc. | INNOVAMATRIX AC (Device) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: ADVANCED WOUND CARE | ||||||
| 11/11/2024 | ConvaTec Inc. | INNOVAMATRIX AC (Device) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: ADVANCED WOUND CARE | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $11.83 | General |
| Category: Immunology | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $1.23 | General |
| Category: Immunology | ||||||
| 11/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $948.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 68 | 14,260 | 37,283 | $6.2M | $2.7M |
| 2022 | 72 | 14,694 | 38,856 | $6.6M | $2.8M |
| 2021 | 70 | 14,744 | 39,617 | $6.4M | $2.8M |
| 2020 | 71 | 14,569 | 34,993 | $5.2M | $1.9M |
Total Patients
58,267
Total Services
150,749
Medicare Billing
$10.1M
Procedure Codes
281
All Medicare Procedures & Services
281 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 23 | 8,100 | $1.2M | $888,890 | 74.8% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 590 | 792 | $867,240 | $328,712 | 37.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 2,046 | 3,927 | $706,682 | $197,122 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 2,037 | 3,057 | $350,511 | $175,017 | 49.9% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 286 | 457 | $297,507 | $136,979 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 670 | 944 | $163,374 | $79,049 | 48.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 1,584 | 2,287 | $281,301 | $73,245 | 26.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 979 | 1,208 | $219,856 | $66,223 | 30.1% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 298 | 342 | $318,744 | $60,464 | 19.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 617 | 716 | $128,164 | $47,682 | 37.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 1,322 | 9,819 | $245,475 | $44,725 | 18.2% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 86 | 101 | $100,798 | $44,549 | 44.2% |
| 14041 | Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.1-30.0 sq cm | Office | 2023 | 64 | 65 | $102,245 | $43,884 | 42.9% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 39 | 126 | $64,025 | $38,472 | 60.1% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 180 | 196 | $137,788 | $38,144 | 27.7% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2023 | 58 | 58 | $73,602 | $32,239 | 43.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 210 | 284 | $77,259 | $30,045 | 38.9% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 319 | 356 | $67,640 | $25,118 | 37.1% |
| 14061 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.1-30.0 sq cm | Office | 2023 | 29 | 30 | $50,550 | $21,483 | 42.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 332 | 575 | $56,448 | $20,834 | 36.9% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Office | 2023 | 198 | 304 | $37,320 | $18,722 | 50.2% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 185 | 198 | $33,066 | $15,466 | 46.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 220 | 220 | $37,670 | $14,837 | 39.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 107 | 123 | $34,809 | $14,216 | 40.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 336 | 390 | $26,730 | $14,015 | 52.4% |
About Dr. Charles Moon, MD
Dr. Charles Moon, MD is a Dermatology healthcare provider based in Cape Girardeau, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487712295.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Moon, MD has received a total of $489,190 in payments from pharmaceutical and medical device companies, with $16,419 received in 2024. These payments were reported across 1,430 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($363,839).
As a Medicare-enrolled provider, Moon has provided services to 58,267 Medicare beneficiaries, totaling 150,749 services with total Medicare billing of $10.1M. Data is available for 4 years (2020–2023), covering 281 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Cape Girardeau, MO
- Active Since 12/05/2006
- Last Updated 01/31/2017
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487712295
Products in Payments
- TALTZ (Drug) $150,518
- Humira (Biological) $102,868
- SKYRIZI (Biological) $43,287
- ILUMYA (Biological) $40,548
- Skyrizi (Biological) $39,040
- Ilumya (Biological) $35,848
- RINVOQ (Biological) $12,462
- HUMIRA (Biological) $6,581
- Otezla (Drug) $1,260
- TREMFYA (Drug) $1,053
- DUPIXENT (Biological) $889.86
- COSENTYX (Biological) $882.59
- Levulan (Drug) $643.95
- Cimzia (Drug) $600.72
- VTAMA (Drug) $452.36
- ADBRY (Biological) $451.86
- XTRAC (Device) $436.35
- EUCRISA (Drug) $391.72
- COSENTYX (Drug) $365.18
- ENSTILAR (Drug) $331.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.